CTOs on the Move

B-One

www.b1.co

 
A few individuals with decades of experience in the U.S. orthopedic industry,came together in 2015 because they saw the need for a first-class company that was Agile,creative and innovative in a global market subject to advancing technologies and changing policies.They had seen the successes of the large companies, but they had witnessed compromises that had to be made.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.b1.co
  • 636 Shelby Street 4th Floor
    Bristol, TN USA 37620
  • Phone: N/A

Executives

Name Title Contact Details

Funding

B-One raised $14M on 03/03/2020

Similar Companies

M H Monteal Biotechnologies

M H Monteal Biotechnologies is a Kirkland, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bodycad

Bodycad helps healthcare professionals and patients achieve their common pursuit of perfection by actualizing personalized orthopedic restorations. Bodycad enables orthopedic surgeons to create a personalized restoration based on the anatomical specifications of their patient using the company`s proprietary Personalized Restoration Software. Surgeons can quickly and efficiently step through the Bodycad PREP (Personalized Restoration Evaluation Process) to scan their patients and create a specific design plan, approve the design, and perform the restoration. The company is committed to providing high-touch education, training and service, including access to Bodycad PREP Techs to help assure surgical success. Bodycad is transforming the current standard of orthopedic implants to help surgeons and patients achieve their mutual goal of a perfect personalized restoration.

McFarlane Medical

McFarlane Medical is a Geneva, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Brownfield Regional Medical Center

Brownfield Regional Medical Center is a Brownfield, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Valeritas

Valeritas is committed to developing and commercializing innovative treatment solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of Type 2 diabetes. Valeritas` portfolio is headlined by the V-Go® disposable insulin delivery device, which is being commercialized and reimbursed in a specialty pharmaceutical model and is distributed through retail pharmacy.